Biological effects assessment in the evaluation of potential reduced-risk tobacco products
Read Online
Share

Biological effects assessment in the evaluation of potential reduced-risk tobacco products

  • 75 Want to read
  • ·
  • 43 Currently reading

Published by Life Sciences Research Office, Inc. in Bethesda, MD .
Written in English

Subjects:

  • Tobacco use -- Health aspects,
  • Smoking -- Health aspects,
  • Tobacco -- Government policy -- United States,
  • Products liability -- Tobacco -- United States

Book details:

Edition Notes

Other titlesThe LSRO report on biological effects assessment in the evaluation of potential reduced-risk tobacco products
StatementAmy M. Brownawell, editor.
ContributionsBrownawell, Amy M., Life Science Research Office.
Classifications
LC ClassificationsRA1242.T6 B54 2007
The Physical Object
Pagination242 p. ;
Number of Pages242
ID Numbers
Open LibraryOL22512768M
ISBN 109780975316788
LC Control Number2007938291
OCLC/WorldCa191699187

Download Biological effects assessment in the evaluation of potential reduced-risk tobacco products

PDF EPUB FB2 MOBI RTF

Biological Effects Assessment in the Evaluation of Potential Reduced-Risk Tobacco Products Report Life Sciences Research Office (): Biological Effects Assessment in the Evalua. LSRO Report: Biological Effects Assessment The distribution or electronic posting of this PDF file is strictly prohibited without the written permission of the Life Sciences Research Office. BIOLOGICAL EFFECTS ASSESSMENT IN THE EVALUATION OF POTENTIAL REDUCED-RISK TOBACCO PRODUCTS EXECUTIVE SUMMARY December Amy M. Brownawell, Ph.D. (b). LSRO also published the report Biological Effects Assessment in the Evaluation of Potential Reduced-Risk Tobacco Products (a) which provided an in-depth review of assays, models, and biomarkers of human disease that could be used during premarketevaluation to arrive at scientific conclusions regarding the comparative risks of potential reduced-risk tobacco products. Several potential reduced exposure products (PREPs) for smokeless tobacco (SLT) users are marketed in the United States, though their effects are largely unknown. These products include some that are low in tobacco-specific nitrosamines (TSNs), like Stonewall, a pressed tobacco tablet, and General snus, a moist snuff product produced in by:

4 Evaluation of Potential Reduced-Risk Tobacco Products. US are due to LC, COPD, and CVD (Centers for Disease Control and Prevention, c). LSRO concluded that the data needed to evaluate risk reduction of PRRTP use in individual smokers must . The goal of this paper is to present a conceptual scientific framework to help structure the evaluation of tobacco products in a way that can support public health efforts to minimize the harm caused by tobacco by: tobacco product use and perceptions of tobacco products' health risk to NCI's Health Information National Trends Survey. Additionally, the Centers for Disease Control and Prevention laboratory is analyzing the chemistry of some newer tobacco products. The tobacco industry also funds research on potential "harm reducing" tobacco products. Given that ST product use in general has harmful effects on health and is addictive, the scientific community should prioritize strategic efforts to: (1) evaluate factors associated with the initiation and use of ST products; (2) determine to what extent the use of ST products results in continued tobacco use, including dual smoking and ST Cited by:

The PHE report added: “The available evidence suggests that heated tobacco products may be considerably less harmful than tobacco cigarettes and more harmful than e-cigarettes.” Vapour products. We’ve developed a framework of scientific tests to assess the reduced-risk potential of vapour products, relative to smoking cigarettes. Quantitative risk assessment (QRA), a scientific, evidence-based analytical process that combines chemical and biological data to quantify the probability and potential impact of some defined risk, is used by regulatory agencies for by: 2. Exposure Assessment LSRO Report EXPOSURE ASSESSMENT IN THE EVALUATION OF POTENTIAL REDUCED-RISK TOBACCO PRODUCTS LSRO Report on EXPOSURE ASSESSMENT IN THE EVALUATION OF POTENTIAL REDUCED-RISK TOBACCO PRODUCTS Expert Committee Richard Dalby, Ph.D. Department of Pharmaceutical Sciences University of Maryland Baltimore, MD . A key part to be examined in an assessment of the reduced risk potential of a novel product is the measurement of the effect on that product on the behaviour of the existing tobacco users. One such necessary assessment is of the abuse liability (abuse potential) of the new product in comparison to other tobacco products currently by: